"The FAME II trial provides new evidence-based guidance demonstrating the profound role that FFR and second generation drug eluting stents can have in improving patient care. We now know that if a lesion is significant as determined by FFR guidance, the stenting procedure will provide a better outcome. With this knowledge, I believe that FFR should become the standard of care for treating patients with stable coronary artery disease and significant coronary narrowings," said Dr Ashwin B Mehta, head, cardiology department, Jaslok Hospital.

"As the sponsor of the FAME family of studies, St Jude Medical is proud to provide the medical community with additional evidence supporting the critically important role that the PressureWire FFR measurement technologies play in improving patient outcomes," said Dr Frank Callaghan, president, cardiovascular division, St Jude Medical."Publication of this groundbreaking research in the New England Journal of Medicine coinciding with a Hot Line session during ESC demonstrates that the role of FFR in guiding medical care has moved to broader and more mainstream acceptance within the cardiology community."